摘要
目的研究人类激肽释放酶基因4(KLK4)与激肽释放酶基因5(KLK5)在卵巢癌组织中的表达水平,探讨其在恶性肿瘤中的作用机制。方法50例卵巢肿瘤组织标本分为恶性肿瘤组(n=23)、交界性肿瘤组(n=6)和正常或良性肿瘤组(对照组,n=21)。采用荧光定量RT-PCR技术对各组卵巢肿瘤组织标本进行检测,获得KLK4与KLK5的表达水平。结果KLK4在卵巢癌中的表达水平显著高于对照组(P<0.05);KLK5在卵巢癌和交界性卵巢肿瘤中的表达水平也显著高于对照组(P<0.001);KLK5在浆液性囊腺癌中的表达水平显著高于其他组织学类型的恶性肿瘤(P<0.05)和对照组(P<0.001),且低分化浆液性囊腺癌的表达水平高于中分化浆液性囊腺癌的表达(P<0.05)。KLK5的表达水平与血清CA125水平呈正相关。结论KLK5在卵巢癌,尤其是浆液性囊腺癌的发生与发展过程中可能具有潜在促进作用。
Objective To study the expression of human kallikrein gene （KLK） 4 and KLK5 in ovarian cancers, and to investigate the pathogenesis in malignant tumors. Methods Fifty specimens of ovarian cancers were divided into three groups ： malignant tumor group （ n = 23 ） , borderline tumor group （ n = 6 ） and control group （ normal or benign tumor, n = 21 ）. Fluorescent quantitative RT-PCR was employed to determine the expression of KLK4 and KLK5 in these specimens. Results The expression of KLK4 in ovarian cancers was significantly higher than that of the control group （ P 〈 0.05 ） , and the expression of KLK5 in ovarian cancers and borderline ovarian tumors was also significantly higher than that of the control group （P 〈0. 001 ）. The expression of KLK5 in serous epithelial carcinomas was higher than that of the other malignant histological types （P 〈 0.05 ）, and was markedly associated with the histological differentiation （ P 〈 0.05 ）. There was a positive relationship between the expression of KLK5 and serum CA125 level. Conclusion KLK5 might play a potential role in the pathogenesis and development of ovarian cancers, especially in serous epithelial carcinomas.
出处
《上海交通大学学报（医学版）》
CAS
CSCD
北大核心
2006年第12期1336-1338,共3页
Journal of Shanghai Jiao tong University:Medical Science
